Examkin

Question

Difficulty: Very hardMonitoring and Treatment Evaluation

A 4141-year-old man is hospitalized for invasive pulmonary aspergillosis. He underwent a deceased-donor renal transplantation 66 months ago. His maintenance immunosuppression regimen consists of tacrolimus, mycophenolate mofetil, and prednisone. His baseline serum creatinine is 1.41.4 mg/dL. The infectious disease service recommends initiating intravenous voriconazole. Which of the following interventions are required regarding this patient's pharmacotherapy and monitoring? (Select all that apply)

  1. Preemptively reduce the tacrolimus dose by approximately 50%50\% and closely monitor serum trough concentrationsAnswer
  2. Obtain a baseline electrocardiogram and monitor the QTc intervalAnswer
  3. C
    Maintain the current tacrolimus dose and check a steady-state trough concentration in 77 days
  4. D
    Discontinue tacrolimus and mycophenolate mofetil entirely until the invasive fungal infection resolves
  5. E
    Order daily high-resolution computed tomography of the chest to monitor the radiographic resolution of the cavitation

Answer

The correct interventions are preemptively reducing the tacrolimus dose by approximately 50%50\% and obtaining a baseline electrocardiogram to monitor the QTc interval.
Voriconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system. Tacrolimus is heavily metabolized by CYP3A4. Co-administration results in a profound reduction in tacrolimus clearance, leading to supratherapeutic levels and severe toxicity (such as nephrotoxicity and neurotoxicity). Therefore, it is mandatory to preemptively reduce the tacrolimus dose (typically by 30%30\% to 50%50\%) and strictly monitor trough levels. Furthermore, voriconazole is well-known to cause significant QTc prolongation, requiring baseline electrocardiography and ongoing monitoring to prevent lethal arrhythmias like torsades de pointes.

Step-by-Step Solution

1
Identify the high-risk drug-drug interaction between the newly prescribed antifungal (voriconazole) and the baseline calcineurin inhibitor (tacrolimus).
Voriconazole is recognized as a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system, which heavily metabolizes tacrolimus.
Understanding pharmacokinetic interactions is critical to prevent severe iatrogenic toxicity when adding new antimicrobial agents.
2
Determine the necessary dose adjustments for the interacting medications.
A preemptive 30%30\% to 50%50\% reduction in the tacrolimus dose is required immediately upon starting voriconazole, alongside rigorous therapeutic drug monitoring of trough levels.
Without preemptive reduction, tacrolimus clearance plummets, causing rapid accumulation, severe nephrotoxicity, and neurotoxicity.
3
Evaluate the direct adverse effect profile of voriconazole to determine additional monitoring needs.
Voriconazole carries a significant risk for dose-dependent QTc prolongation.
Baseline electrocardiography and ongoing QTc monitoring are mandatory to mitigate the risk of fatal arrhythmias like torsades de pointes.

Key Concept

When initiating a strong CYP3A4 inhibitor such as voriconazole in a patient taking a calcineurin inhibitor like tacrolimus, preemptive dose reduction of the calcineurin inhibitor and rigorous monitoring of drug levels and QTc intervals are mandatory to prevent severe toxicity.
Estimated Time:1m 30s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic